The Study Of Clinicopathologic Characteristics Of Invasive Papillary Carcinoma Of The Breast And The Preliminary Study Of Nek2C And The Breast Carcinoma

Part1ObjectiveAlthough patients with invasive papillary carcinoma (IPC) often have favorable prognoses, it remains unclear if this special type of breast cancer represents a distinct morphological entity with its own biological features and clinical behavior, distinct from those of invasive ductal carcinoma (IDC) and whether its four molecular subtypes are associated with different prognoses or not.Methods284IPC samples were collected from January2000to May2011.300IDC cases were selected randomly from13,428cases of IDC during the same periods. We assessed the clinicopathologic characteristics, molecular features, and prognostic value of IPC (n=284) and compared them to those of IDC (n=300). Clinicopathologic features and survival status of the four subtypes of IPC were also evaluated.ResuItsRelative to IDC, IPC had different age at diagnosis, tumor grade, lymph node status, and menopausal status (P<0.05). IPC was associated with a better5-year overall survival rate (OS)(92.77%vs87.95%) and disease-free survival rate (DFS)(87.95%vs80.72%) than IDC. Tumors of the luminal A subtype had a better5-year OS (97.78%) and DFS (95.56%) than other subtypes.ConclusionsThe biologic behavior of IPC is more favorable than that of IDC. The chance of pure IPC causing death without an intervening event of a different histologic type is exceptionally low. Luminal A subtypes have better outcomes when compared to the other subtypes. Part2Objecti veThe serine/threonine kinase Nek2has been proposed to be required for the progression of breast cancer. The aim of this study was to investigate the expression of Nek2C, which is the splice variant of Nek2, and the role it played in different stages of breast cancer.MethodsIn this study, we investigated the role of Nek2C in breast cancer MCF10cell lines including MCF10A, MCF10AT, MCF10DCIS.com and MCF10Cal, using RNA interference and plasmid transfection, as well as breast tissure which contained normal breast tissue (NBT), atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC). We detected the expression of Nek2C in mRNA levels in MCF10cell lines and in human breast samples.ResuItsOur study revealed that the mRNA expression of Nek2C was significantly up-regulated in MCF10DCIS.com and MCF10Cal cell lines as well as in human primary breast cancer tissue (DCIS and IDC). As expected, Nek2C down-regulation, using RNA interference, decreased the survival, invasion and migration of MCF10DCIS.com and MCF10Cal cells. Consistent with this. Nek2C up-regulation of MCF10A and MCF10AT cells using plasmid transfection had increased the survival ability of these cells. Our study also presented a correlation between Nek2C mRNA expression levels and tumor grade.ConclusionsTaken together, our findings sustained that Nek2C played great effect on breast cancer occurrence, and Nek2C inhibition may be a useful therapeutic approach to target human breast tumors.